BIOLINERX LTD/S (BLRX) Given Consensus Recommendation of “Buy” by Analysts

Share on StockTwits

Shares of BIOLINERX LTD/S (NASDAQ:BLRX) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $3.00.

BLRX has been the topic of several research reports. HC Wainwright set a $4.00 price objective on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Monday, October 22nd. Zacks Investment Research raised shares of BIOLINERX LTD/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 7th. Maxim Group reissued a “buy” rating and set a $2.00 price objective on shares of BIOLINERX LTD/S in a research report on Thursday, November 8th. Finally, Oppenheimer set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Friday, November 9th.

Several hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new stake in shares of BIOLINERX LTD/S in the 4th quarter worth $25,000. Menta Capital LLC acquired a new stake in shares of BIOLINERX LTD/S in the 4th quarter worth $33,000. ETF Managers Group LLC lifted its stake in shares of BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 166,386 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of BIOLINERX LTD/S in the 3rd quarter worth $1,412,000. Institutional investors own 36.11% of the company’s stock.

BIOLINERX LTD/S stock traded down $0.01 during midday trading on Tuesday, hitting $0.40. 3,161,000 shares of the company’s stock were exchanged, compared to its average volume of 1,589,042. BIOLINERX LTD/S has a 12-month low of $0.38 and a 12-month high of $1.84. The company has a market capitalization of $43.16 million, a P/E ratio of -1.48 and a beta of 1.84.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: What is a Derivative?

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.